Pharmaceutical Technology-09-02-2011
Pharmaceutical Technology
A Design of Experiments for Tablet Compression
September 02, 2011
Peer-Reviewed Research
35
9
The author prepared and analyzed a detailed design of experiments for the manufacture of a simple tablet formulation. The aim was to test whether tablet hardness and weight could be controlled during the compression process by adjusting certain machine parameters.
Q&A with John Plachetka, POZEN
September 02, 2011
Industry Leaders
35
9
A Q&A with John Plachetka, chair, president, and CEO of POZEN, on recent industry trends.
Surface Neutralization System
September 02, 2011
Peer-Reviewed Research
35
9
A new, robust method for protein elution from ceramic hydroxyapatite.
Washington Report: Manufacturers and FDA Gear Up for User-Fee Action
September 02, 2011
Washington Report
35
9
PDUFA renewal legislation sets stage for new policies affecting revenue, resarch, and oversight.
Knowing is Half the Battle
September 02, 2011
Agent-in Place
35
9
Being aware of a forthcoming inspection or how a product was made can make a huge difference.
Retrospection and Introspection at FDA
September 02, 2011
From The Editor
35
9
A report commissioned by FDA evaluates the QbD program.
Web 2.0 for Pharma Innovation
September 02, 2011
PharmTech Talk
35
9
Internal and external Web-based communities are changing how pharma companies can innovate.
FDA Perspectives: Understanding Challenges to Quality by Design
September 02, 2011
Special Feature
35
9
Directors from FDA's Center for Drug Evaluation and Research summarize findings in an FDA-commissioned report on QbD and propose actions the agency can take to encourage full-scale QbD implementation.
Report from Latin America
September 02, 2011
In the Field
35
9
Growth and change in Brazil and Mexico offer key opportunities for the region's pharmaceutical industry.
The EU Debt Crisis and CMOs
September 02, 2011
Outsourcing Outlook
35
9
The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
A Pharmaceutical Company's View on Supply-Chain Security: A Perspective from Pfizer
September 02, 2011
Online Exclusive
35
9
The author offers perspectives on ways in which pharmaceutical companies and other stakeholders in the supply chain can confront the threat of counterfeit products, cargo theft, illegal diversion, and economically motivated adulteration.
Verification through Telecommunication
September 02, 2011
Packaging Forum
35
9
Smartphones could become the product-authentication tool of choice. Contains online bonus material.
Inside ICH: Quality Implementation and Harmonization Continue
September 02, 2011
Inside ICH
35
9
A summary of the latest steering committee and expert working groups' meeting.
Regulators Debate Methods for Producing Water for Injection
September 02, 2011
Special Report
35
9
Might European officials reverse their position on acceptable production methods?
The Case for Pediatric Exclusivity
September 02, 2011
BioForum
35
9
Reauthorization of pediatric exclusivity provisions looms in 2012 and debates begin anew.
Global Healthcare on the Ground: IFPMA Engages Global Bodies to Push Health Efforts Forward
September 02, 2011
In the Field
35
9
International Federation of Pharmaceutical Manufacturers and Associations takes global action to improve public health.
Continuous Progress in Continuous Manufacturing
September 02, 2011
Special Report
35
9
Industry buy-in is increasing as pharma companies proceed with select projects and research.
In the Spotlight September 2011
September 02, 2011
In the Spotlight
35
9
New product reviews for September 2011 focusing on manufacturing.
Formulation Development Forum: Microscale Hydrogels
September 02, 2011
Pharma Ingredients
35
9
Researchers at MIT and Harvard University report on new methods for producing microscale hydrogels.
Where in the World is the US Pharmacopeia?
September 02, 2011
Viewpoint
35
9
After a series of structural changes, the author wonders whether USP is undergoing an identity crisis. USP CEO Roger L. Williams responds.
PQRI Case Study (3): Facility Biocontainment and Inactivation
September 02, 2011
Special Feature
35
9
The third in a series of eight case studies from the Product Quality Research Institute focuses on facility biocontainment and inactivation.
Building Toolboxes in Pursuit of Single-Enantiomer Drugs
September 02, 2011
Pharma Ingredients
35
9
Biocatalysis, chemocatalysis, and other chiral technologies continue to attract the investment dollars of CMOs and fine-chemical companies.
Pharmaceutical Technology, September 2011 Issue (PDF)
September 02, 2011
35
9
Click the title above to open the Pharmaceutical Technology September 2011 issue in an interactive PDF format.